Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyHoward S. Höchster, Eric Hedrick, Yousif Abubakr et al.|Journal of Clinical Oncology|2008Cited by 623
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaCraig H. Moskowitz, Andrew D. Zelenetz, Joseph R. Bertino et al.|Journal of Clinical Oncology|1999Cited by 303
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-StudyH. S. Hochster, Barrett H. Childs, Lowell L. Hart et al.|Journal of Clinical Oncology|2006Cited by 137
Molecular characterization and management of secondary resistance to serial TRK inhibitors.Michael J. Nathenson, George D. Demetri, Karan Malik et al.|Journal of Clinical Oncology|2019Cited by 1